6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome (NAIF)
Recruitment status was: Recruiting
Background: Systemic corticosteroids are considered in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score.
Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical course of multiple organ dysfunction syndrome (MODS).
Design: Multi-center, double-blind, randomized, placebo-controlled.
Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous solution). The duration of the study medication administration protocol is 32 days (1).
- All cause Intensive Care Unit (ICU) and 28-day mortality
- Organ dysfunction score on days 4, 7, 14, and 28 of the protocol.
Multiple Organ Dysfunction Syndrome
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome|
- All cause ICU and 28-day mortality [ Time Frame: 28 days ]
- Organ dysfunction score on days 4, 7, 14, and 28 of the protocol [ Time Frame: Days 4, 7, 14, and 28. ]
- Mortality [ Time Frame: 28 days ]
- Morbidity: Duration of mechanical ventilation and endotracheal intubation (also a surrogate for acute steroid myopathy) [ Time Frame: 28 days ]
- Length of ICU-stay [ Time Frame: 28 days ]
- Complications of steroid therapy [ Time Frame: 28 days ]
- Infections acquired during the protocol [ Time Frame: 28 days ]
- Other complications (hyperglycemia, GI bleeding, acute myopathy, pneumothorax) [ Time Frame: 28 days ]
- Adrenal reserve as evaluated by adrenocorticotropic hormone (ACTH) test. [ Time Frame: Baseline ]
|Study Start Date:||August 2005|
|Estimated Study Completion Date:||July 2008|
|Estimated Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
iv, 2 mg/kg/day, qid
Placebo Comparator: Comparator
iv, 2 mg/kg/day, qid
Hide Detailed Description
Worldwide intensive care physicians consider administering systemic corticosteroids in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Data from recent small studies performed in patients with unresolving ARDS (1;2) suggest survival benefits associated with rescue therapy with relatively prolonged courses of corticosteroids. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score. It has been suggested that that the integrity of the hypothalamic-pituitary-adrenal axis may be impaired in this patient subset (3;4)
To evaluate the safety and effectiveness of a non-selective anti-inflammatory strategy, i.e. 6-methyl-prednisolone, on persistent and unresolving inflammatory states, i.e. multiple organ dysfunction syndrome, on the degree of organ dysfunction and mortality.
Multi-center, double-blind, randomized, placebo-controlled. Randomization and data entry is internet based (htpp://www.webnaif.com). Patients will be randomized through a computer-generated random-number table and stratified by center in blocs of 6. Sample size, by group 120 patients. The study is powered to detect a 20% reduction in mortality, from 50% to 30% in 100 patients per study group at the 5% significance level with a power of 80%. An additional 20% (n=20) per group have been planned to compensate for losses.
Main Inclusion Criteria:
- Patients with established, unresolving, refractory MODS, in whom all reversible and treatable causes of persistent MODS have been treated or ruled out.
- Patients under endotracheal intubation and mechanical ventilation for at least 7 days.
- Aggregate Multiple Organ Dysfunction Score (5) of greater than 8 over the first seven days of mechanical ventilation and greater than 5 on the day of inclusion.
- Written informed consent to participate in the trial signed by next of kin or other authorized person.
Additional Inclusion Criteria:
- Main cause or disease at admission: Adequate "source control" is required and refers to optimal, complete, and definitive surgical and/or medical therapy.
- Infectious causes of persistence of MODS have reasonably been ruled out on clinical or other grounds (infectious endocarditis, undrained abscesses like sinusitis, empyema or abdominal pus). Consider sampling for culture of broncho-alveolar lavage fluid, protected specimen brush or other (empyema fluid, lung tissue) in order to rule out respiratory infection, as well as intra-vascular catheter change and culture.
- Present or previous infections, either documented or strongly suspected, have been treated for at least 3 days before inclusion.
- Supportive Care: Optimal hemodynamic, renal, hematologic, nutritional "supportive care" is provided.
- Decision not to provide full support.
Immune status and steroid therapy.
- Currently indicated for chronic or concurrent disease (meningitis, auto-immune disease, asthma, acute exacerbation of COPD, or other). Inhaled steroids are allowed.
- Administered during current admission (> 20 mg/day of 6-methyl-prednisolone or equivalent for >48 hours).
- Chronic steroid therapy prior to current admission (> 20 mg of 6-methyl-prednisolone or equivalent/day for > 1 month during previous 3 months).
- Other immune-suppressive therapy within the previous 6 months.
- Known AIDS.
- Neutropenia < 500/mcl.
- Preceding organ transplantation.
- Irreversible and or ultimately fatal clinical conditions like metastatic malignant disease or cardiogenic shock caused by coronary artery disease.
- Presence of invasive fungal infection
Other significant pre-existing underlying chronic diseases:
- Severe parenchymal liver disease (Child-Pugh grade C)
- Severe and irreversible acute or chronic central nervous system disease.
- Severe end-stage chronic obstructive pulmonary disease (home oxygen or more than 1 exacerbation in previous year)
- End-stage renal disease (Chronic dialysis).
- Age less than 18 years.
- Morbid obesity: body mass index above 40.
- Recent (last 3 months) upper GI hemorrhage.
- Extensive burns (>30% BSA)
- Known allergy to steroids.
- Written informed consent not available.
Intravenous administration of 6-methyl-prednisolone or placebo(aqueous solution). The duration of the study medication administration protocol is 32 days (1):
- Initial iv loading dose of 160 mg.
An iv bolus injection of 6-methyl-prednisolone is administered every 6 hours:
- 40 mg on days 1 to 14,
- 20 mg on days 15 to 21,
- 10 mg on days 22 to 28,
- 5 mg on days 29 and 30, and
- 2.5 mg on days 31 and 32.
Informed consent form and information sheet have been reviewed and approved by the regional Ethics Committee of Madrid (10 centres), the local review boards of the other participating centres, and the Agencia Española del Medicamento (Spanish Ministry of Health).
The study protocol has been approved by the regional Ethics Committee of Madrid (10 centres), the local review boards of the other participating centres, and the Agencia Española del Medicamento (Spanish Ministry of Health).
The independent Data Monitoring Committee (DMC) will have real-time access to the main variable "28-day mortality" (and allocation to study group "A" or "B") and will propose premature interruption of the trial based on sequential analysis if significant differences become apparent. The DMC will perform 5 interim analysis, one every 48 included patients and the criterium used will be a statistically significant difference at the level of p < 0,01 (S.J. Pocock. Clinical Trials. A practical Approach. John Wiley & Sons. New York. 1994).
- All cause ICU and 28-day mortality
- Organ dysfunction score on days 4, 7, 14, and 28 of the protocol.
Planned Subgroup Analysis:
No subgroup analysis are planned.
The investigators will use the NIH Toxicity Form with a scale from 1 to 5. Severe adverse events in this severely ill population are precisely defined and require immediate (less than 24 hours) communication to the study website. The DMC will have access to the variables that define and describe the SAEs.
Main comparisons are 28-day and ICU mortality between study groups (chi square test for percentages and log-rank test Kaplan-Meier survival curves. Multiple organ dysfunction score and Sequential Organ Failure Assessment score will be compared at baseline and on days 4, 7, 14 and 28 (Student's t test and/or non-parametric tests). Independent risk factors for mortality will be studied by multivariate analysis (Cox regression) of significant comparisons of the univariate analysis. Analysis sample according to the principle of intention to treat.
The finishing date is 18 months after the first inclusion at each centre. Scheduled beginning of the trial is August 2005
First trimester 2007.
A large study like the present trial is required to obtain definitive data about safety and effectiveness of 6-methyl-prednisolone administered as rescue therapy in patients with the multiple organ dysfunction syndrome.
- Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280(2):159-65.
- Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Jr., Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am.J.Surg. 1995;170(6):591-5.
- Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003;31(1):141-5.
- Loisa P, Rinne T, Kaukinen S. Adrenocortical function and multiple organ failure in severe sepsis. Acta Anaesthesiol.Scand. 2002;46(2):145-51.
- Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638-52.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00127985
|Contact: Miguel Sanchez, MD, PhD||34-91-887-8100 ext email@example.com|
|Hospital Principe de Asturias||Recruiting|
|Alcala de Henares, Madrid, Spain, 28805|
|Contact: Raul De Pablo 34-91-8871-8100 ext 2205 firstname.lastname@example.org|
|Principal Investigator: Raul De Pablo, MD|
|Contact: Antoni Torres, MD, PhD|
|Principal Investigator: Antoni Torres, MD, PhD.|
|Sub-Investigator: Juan Ramón Badía, MD, PhD|
|Hospital Universitario de la Princesa||Recruiting|
|Madrid, Spain, 28006|
|Contact: Antonio Reyes, MD., PhD. 34-91-520-2200 Areyes.email@example.com|
|Contact: Fernando Lopez, MD., PhD. 34-91-520-2200 firstname.lastname@example.org|
|Principal Investigator: Antonio Reyes, MD., PhD.|
|Sub-Investigator: Fernando - Lopez, MD, PhD|
|Francisco Ortuño Anderiz||Recruiting|
|Madrid, Spain, 28040|
|Contact: Francisco - Ortuño Anderiz, MD 34-91-330-3223 email@example.com|
|Sub-Investigator: Fernando - Martinez Sagasti, MD, PhD|
|Contact: Manuel Alvarez, MD, PhD.|
|Contact: Juan Jose Oñoro, MD|
|Principal Investigator: Manuel Alvarez, MD, PhD|
|María Mar Cruz Acuaroni||Recruiting|
|Toledo, Spain, 45004|
|Contact: Maria Mar - Cruz Acuaroni, MD 34-925-26-9237 firstname.lastname@example.org|
|Contact: Maria José - Pérez Pedrero, MD 34-925-26-9237|
|Principal Investigator: Maria Mar - Cruz Acuaroni, MD|
|Sub-Investigator: Maria Jose - Perez Pedrero, MD|
|Study Chair:||Miguel Sanchez, MD, PhD||Hosp. Univ. Principe de Asturias|